Phase I Study of Penclomedine and Its Neurotoxicity
Author Information
Author(s): DI Jodrell, A Bowman, M Stewart, N Dunlop, R French, A MacLellan, J Cummings, JF Smyth
Primary Institution: ICRF Medical Oncology Unit, Western General Hospital, Edinburgh
Hypothesis
What is the maximum tolerated dose (MTD) of penclomedine when administered intravenously?
Conclusion
The study found that the dose-limiting toxicity of penclomedine was dizziness and associated cerebellar ataxia at the maximum dose tested.
Supporting Evidence
- Neurotoxicity was the dose-limiting toxicity observed in patients.
- Common toxicity criteria grade II vomiting was recorded at all dose levels.
- Thirteen out of sixteen patients had received previous chemotherapy.
Takeaway
Doctors tested a new cancer drug called penclomedine on 16 patients to see how much they could safely give without causing serious side effects, but they found that it made some people feel dizzy.
Methodology
This was an open non-randomized study with dose escalation to determine the MTD and toxicity profile of penclomedine.
Limitations
The study was limited by the small sample size and the absence of anti-tumor responses.
Participant Demographics
Eight men and eight women, median age 59 years (range 39-73 years), with good performance status.
Want to read the original?
Access the complete publication on the publisher's website